Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)

Dianthus Therapeutics has reported EBITDA over the past 8 years, most recently at -$36.7 million for Q3 2025.

  • Quarterly results put EBITDA at -$36.7 million for Q3 2025, down 50.07% from a year ago — trailing twelve months through Sep 2025 was -$126.9 million (down 91.04% YoY), and the annual figure for FY2024 was -$84.9 million, down 95.88%.
  • EBITDA for Q3 2025 was -$36.7 million at Dianthus Therapeutics, down from -$31.8 million in the prior quarter.
  • Over the last five years, EBITDA for DNTH hit a ceiling of -$7.0 million in Q1 2023 and a floor of -$36.7 million in Q3 2025.
  • Median EBITDA over the past 4 years was -$17.4 million (2022), compared with a mean of -$19.5 million.
  • Biggest five-year swings in EBITDA: surged 70.14% in 2023 and later tumbled 176.02% in 2024.
  • Dianthus Therapeutics' EBITDA stood at -$10.1 million in 2022, then fell by 3.8% to -$10.5 million in 2023, then plummeted by 176.02% to -$29.0 million in 2024, then dropped by 26.49% to -$36.7 million in 2025.
  • The last three reported values for EBITDA were -$36.7 million (Q3 2025), -$31.8 million (Q2 2025), and -$29.3 million (Q1 2025) per Business Quant data.